New blood test to detect colon cancer clears FDA approval
The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.
How this was made
The 30-second read
Why it matters
Traders should view this as a regulatory milestone for Freenome’s colorectal cancer franchise, with the key swing factors being reimbursement, pricing, and real-world screening uptake starting in the fall.
Market read
Regulatory approval of a second blood-based colorectal cancer screening test can re-rate oncology diagnostics sentiment, but the magnitude depends on commercialization details not provided here.
What to watch
The article notes comparative effectiveness uncertainty and Stage 1 detection differences versus Shield, which could influence clinician adoption and long-term market penetration.
Background
The FDA approved SimpleScreen CRC, a blood-based DNA signal test for colorectal cancer screening in average-risk adults aged 45 and older, with positive results requiring colonoscopy confirmation.
Ticker impact
Guardant Health’s Shield test is referenced as the prior FDA-approved colorectal cancer blood test, with noted lower Stage 1 detection.
Limited immediate impact unless investors interpret SimpleScreen’s results as materially superior for early-stage detection.
Guardant is not the subject of the approval; the article only discusses Shield’s prior approval and comparative effectiveness, without new Shield-specific regulatory or trial updates.
Abbott’s cancer diagnostics business is mentioned via a chief medical officer comment and a partnership expected to make SimpleScreen available this fall.
No strong standalone catalyst for ABT without disclosed contract economics or scale.
The article does not provide the partnership’s financial terms, scope, or exclusivity, so the incremental impact on ABT is speculative.
Market effects
Adds another FDA-approved liquid biopsy option for colorectal cancer screening, potentially intensifying competition in oncology diagnostics and raising expectations for noninvasive screening adoption.
Primarily US-focused screening and reimbursement dynamics, with potential spillover to US healthcare providers and payers.
Could accelerate global interest in blood-based colorectal cancer screening, though the article only confirms US FDA approval.
Counterpoint
FDA approval does not guarantee payer coverage or patient uptake; if pricing or reimbursement is unfavorable, near-term commercial impact may be muted.
Key entities
- companyFreenome
California biotech company that makes SimpleScreen, the FDA-approved blood test for colorectal cancer screening.
- productSimpleScreen CRC
Blood-based DNA signal test for colorectal cancer screening in adults aged 45+ at average risk.
- companyGuardant Health
Referenced for its FDA-approved Shield test, used as a comparative benchmark in the article.
- companyAbbott
Referenced via a diagnostics executive comment and expected partnership for fall availability of SimpleScreen.
- regulatorFDA
Approved SimpleScreen CRC for colorectal cancer screening.
